1. Home
  2. IKT vs SHMD Comparison

IKT vs SHMD Comparison

Compare IKT & SHMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

N/A

Current Price

$1.39

Market Cap

209.3M

Sector

Health Care

ML Signal

N/A

Logo SCHMID Group N.V. Class A Ordinary Shares

SHMD

SCHMID Group N.V. Class A Ordinary Shares

N/A

Current Price

$2.03

Market Cap

198.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
IKT
SHMD
Founded
2008
1864
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
209.3M
198.2M
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
IKT
SHMD
Price
$1.39
$2.03
Analyst Decision
Strong Buy
Analyst Count
9
0
Target Price
★ $5.55
N/A
AVG Volume (30 Days)
518.1K
★ 768.6K
Earning Date
11-10-2026
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 57.76
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$49.82
Revenue Next Year
N/A
$48.26
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.37
$1.86
52 Week High
$2.61
$10.65

Technical Indicators

Market Signals
Indicator
IKT
SHMD
Relative Strength Index (RSI) 36.37 32.14
Support Level N/A N/A
Resistance Level $1.71 $3.65
Average True Range (ATR) 0.12 0.24
MACD 0.00 -0.02
Stochastic Oscillator 2.82 10.20

Price Performance

Historical Comparison
IKT
SHMD

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

About SHMD SCHMID Group N.V. Class A Ordinary Shares

Schmid Group NV is a supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).

Share on Social Networks: